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Systemic lupus erythematosus (SLE) is a human autoimmune disease of unknown etiology. Clinical,
serologic, immunologic, and pathologic findings are highly variable in different patients and at different times
in the same patient. Murine and canine animal models of SLE have been found with clinicopathologic
abnormalities resembling those observed in humans. Each animal model has unique characteristics; taken
together they reflect the spectrum of disease in human SLE.
Investigations in the animals have suggested that genetic, hormonal, immunologic, viral, and other
environmental factors contribute to and modify the expression of disease. Where analogous studies are
available for humans, the same factors have been found to modify disease expression in a similar fashion.
Together, these studies have helped to clarify the multifactorial basis for SLE.
The best characterized abnormalities are immunologic. These include excessive B cell function with the
formation of large amounts of autoantibodies, and T cell abnormalities which include defects in T cell
regulatory function as well as certain T cell effector functions.
The animal models of SLE also serve as convenient test subjects for newer therapeutic modalities. It is
hoped that further study of the animal models will provide a more rational approach to therapeutic
modulation of disease in humans with SLE.
INTRODUCTION
Systemic lupus erythematosus (SLE) is an autoimmune multisystem disease
characterized in humans and certain animals by dermatitis, photosensitivity, alope-
cia, arthritis, serositis, fever, anemia, glomerulonephritis, and/or central nervous
system aberrations. Serologic abnormalities include depressed complement and
antibodies to nuclear constituents, leukocytes, and erythrocytes. Although SLE has
long been considered an autoimmune disease on the basis of a plethora of autoanti-
bodies, the cause of this illness has remained elusive with investigators having
implicated genetic, viral, and immunologic factors. Since the spectrum of disease is
immense, SLE may actually represent many different diseases with a similar common
pathway of illness. Alternatively, relatively few diseases may be represented, the
differences explained by genetic and/or environmental factors.
Our working hypothesis has been that SLE is a multifactorial disease in both
humans and animals (Table 1). Some factors may be necessary, but not sufficient, for
the disease expression. Different factors may carry different wieght in different
individuals, and understanding of the contributing factors has evolved from studies
utilizing animal models.
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TABLE I
Pathogenetic Factors in Autoimmunity with Special Reference to Systemic Lupus Erythematosus
Factor Human New Zealand Mice Canine
Genetic B-cell antigen association Limited number of ?
Family studies autosomal genes
Immune B-cell excesses B-cell excesses ?
T-cell deficiencies T-cell deficiencies
Viral and other Viruses and other environmental C-type virus may act ? Vertically
"Environmental" insults may stimulate the as a B-cell mitogen transmissible
Factors immune system, especially B- virus
cell function
MRL/ I and BXSB mice have not been studied.
In 1959, Bielchowsky found that New Zealand Black (NZB) mice die prematurely
with hepatosplenomegaly and autoimmune hemolytic anemia, the first report of a
spontaneously occurring autoimmune disease in an experimental animal [1]. Subse-
quently, Helyer and Howie observed the spontaneous appearance of a different
autoimmune disease in New Zealand Black x New Zealand White (NZB x NZW) F I
hybrid mice, characterized by antinuclear antibodies, lupus erythematosus cells (LE
cells), glomerulonephritis, and premature death secondary to renal failure, features
not unlike those found in human SLE [2]. A similar SLE-like disease has been found
in dogs [3] and in the past two years, additional mouse models of SLE have been
reported [4]. Studies utilizing these SLE animal models have led to a better
understanding of not only human SLE, but of a variety of autoimmune phenomena,
as well as associations between autoimmunity and neoplasia.
Features ofthe NZB Murine Model
NZB mice spontaneously develop autoimmune hemolytic anemia, immune com-
plex renal disease, and excessive lymphoreticular proliferation. The anti-erythrocyte
antibody is initially detected after three months of age by the direct antiglobulin test
(Direct Coomb's) and after several more months may be detected by the indirect
antiglobulin test (Indirect Coombs). These antibodies are initially of the IgG
subclasses [5]; some are directed against cryptic antigenic determinants, such as the
X-antigen which is exposed only after partial digestion of the erythrocyte membrane
[6]. Only NZB mice and their hybrids are capable of generating these anti-X-
antibodies [7]. Furthermore, these antibodies are represented in IgG,, IgG2a, and
IgG2b subclasses, suggesting that more than one clone of antibody producing cells is
active, making a clonal malignancy unlikely [8]. This activation of polyclonal
antibody responses to cryptic autoantigen may represent activation ofrepressed anti-
self clones of lymphocytes.
By nine to eighteen months of age the anti-erythrocyte antibodies are of the IgG
and IgM classes and directed against both cryptic and non-cryptic antigens [9]. The
mice develop severe anemia with reticulocytosis, spherocytosis, decreased in vivo
erythrocyte survival, increased erythrocyte osmotic fragility, marked splenomegaly,
and extramedullary hematopoiesis. In some of these mice a membraneous and/or a
proliferative glomerulonephritis may be found, often without clinically significant
deterioration of renal function [9]. A minority of NZB mice are found to have LE
cells or positive fluorescent antinuclear antibody tests [10] though they do sponta-
neously develop antibodies to single-stranded DNA. In addition, they produce large
amounts of IgM antibodies to thymocytes [11]. These naturally occurring thymo-
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cytotoxic antibodies (NTA) increase in titer as the NZB mice age and may play an
important role in the development of autoimmunity. Most of the NZB mice die of
their autoimmune hemolytic anemia by 18-20 months of age, while some ofthe mice
die with lymphoid malignancies.
Features ofthe NZB/NZW F1 Murine Model
The mating of NZB mice with non-autoimmune New Zealand White mice results
in an F, hybrid in which the predominant autoimmune phenomenon is changed from
the NZB hemolytic anemia to a severe proliferative glomerulonephritis. In addition,
these F, mice all develop LE cells and high titers of antinuclear antibodies, making
them a better model for human SLE than NZB mice. (NZB x NZW) F, and
(NZW x NZB) F, mice had very similar clinical and serological abnormalities,
making extremely unlikely the possibility that murine SLE was either sex-linked or
transmitted via a maternal-fetal interaction in utero or via colostrum [12]. Ovum
transplantation studies confirmed these findings [13]. However, comparison of
(NZB x NZW) F1 littermates revealed that the females have a more rapid progression
of disease with death by nine to twelve months of age secondary to renal failure; the
male littermates live 100-150 days longer, having a more gradual progression of
disease [14].
By one month of age, female (NZB x NZW) F1 mice may have detectable
antinuclear antibodies which increase with age and are heterogeneous, consisting of
antibodies to single- and double-stranded DNA and RNA, nucleic acid-protein
complexes, and nuclear proteins. Afterfour months ofage the LE cells may be found.
Between six and nine months of age, immunoglobulins and complement can be
detected in glomeruli of (NZB x NZW) F1 mice by immunofluorescence [15].
Electron microscopic studies reveal electron dense deposits (immune complexes)
initially in the mesangium followed by subendothelial deposits and then subepithelial
deposits. Later there is diffuse proliferation of Bowman's Capsule with basement
membrane thickening, focal necrosis, and glomerular sclerosis. These histologic
findings are associated with progressive proteinuria, azotemia, and death by nine to
twelve months of age [16]. Death due to a lymphoid malignancy is seen less often
than in NZB mice, possibly due to an early death from renal failure.
Since female (NZB x NZW) F1 mice have an accelerated form of SLE, sex
hormones have been suspected of playing a significant role on the expression of
disease. Recent studies have supported this theory. Comparison ofage-matched male
and female castrated and/or sex hormone treated (NZB x NZW) F1 mice, followed
with serial determinations of urinary protein, serum anti-DNA antibody titers, and
longevity, revealed that androgens exert a protective effect [17]. When pre- or post-
pubertally castrated female mice were treated with androgens (in subcutaneous
continuous-release capsules), they had reduced proteinuria and prolonged survival,
although post-pubertal treatment with androgens had little effect on anti-DNA
antibody production. Estrogens do not appear to be as important in accelerating
disease as androgens are in retarding autoimmunity; however, administration of an
estrogen inhibitor has retarded disease, leaving an accelerating role for estrogens as a
possibility [18].
Genetic Factors in New Zealand Murine Models
Genetic analyses of the inheritance of autoimmune traits have been performed by
mating NZB mice with other New Zealand strains and with non-New Zealand strains.
Crosses of NZB and NZC (New Zealand Chocolate) mice and F, backcrosses to the
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NZC suggested that both a dominant and a recessive gene are responsible for anti-
erythrocyte antibodies [19,20]. Crosses of NZB and AKR (non-autoimmune, non-
New Zealand) mice and F, backcrosses to the AKR suggested that three to five
unlinked genes control the production ofanti-erythrocyte antibodies, and that one of
the genes is on the X chromosone [21,22]. These and additional crosses all suggest
that more than one gene, at least one of which may not be uniquely associated with
the NZB strain, is involved in the phenotypic expression of Coomb's positivity [23].
Furthermore when (NZB x NZW) F1 mice were studied, the NZW contributed a
modifying gene that in the presence of the NZB gene allowed for a positive anti-
nuclear antibody response [10]. Recent evidence suggests that a single dominant gene
controls the spontaneous expression of anti-single-stranded DNA antibodies, one of
the anti-nuclear antibodies [24].
The spontaneous production ofanti-thymocyte antibodies (NTA) has been studied
using NZB and DBA/2 (non-autoimmune, non-New Zealand) mice, their F, and F,
backcrosses [24]. Analysis suggests that NTA production is inherited as a single
codominant trait. Whether the quantity of autoantibody production is controlled by
gene dosage effects or by regulatory genes is uncertain.
The occurrence of lupus glomerulonephritis in (NZB x NZW) F1 mice appears to
be dependent on the interaction of at least two dominant or codominant genes, at
least one gene from each parent [25]. However, since a multitude of immune
complexes may contribute to lupus nephritis, this phenotypic expression of autoim-
munity may be the most difficult to subject to genetic analysis.
These and many other genetic studies have suffered from the lack of a primary gene
product for study. Therefore investigators have had to choose phenotypic markers
which vary with age. However, recent advances in immunogenetics have resulted in
the identification of proteins encoded for in specific genes located both in and outside
the major histocompatability complex (H-2) of mice. It is hoped that immune
response gene products will provide better markers for the genetic analysis of
autoimmunity in the future.
Viruses and New Zealand Murine Models
The role of viruses in the etiology and/ or pathogenesis of autoimmunity in NZB
and (NZB x NZW) F1 mice is uncertain. A C-type virus can be isolated from these
mice and passed to other species but not other mice (xenotropic virus). In addition,
viral antigen-antibody complexes can be found in (NZB x NZW) F1 glomeruli [26].
Infection of (NZB x NZW) F1 mice with lymphocytic choriomeningitis virus or
polyoma virus accelerates disease [27], while infection with lactic dehydrogenase
virus or treatment with viral-like statalon retards disease [28]. This suggests that
viruses can at least alter the expression of autoimmunity. Recent studies suggest that
more than one virus may combine genomes, resulting in a "new" or "pseudotype"
virus [29]. Such a "new" virus can be hypothesized as contributing to the develop-
ment of autoimmunity. On the other hand, many strains of mice have similar viruses
without autoimmune disease [30]. Thus the debate continues as to the role ofviruses
as well as genetics in the development of autoimmunity; most likely both contribute.
IMMUNOLOGIC ABNORMALITIES IN NEW ZEALAND MICE
Three broad categories of cell types are thought to be fundamental for an effective
immune response. One of these cells is the macrophage, an antigen processing and
presenting cell; the other two are lymphocytes. The lymphocytes which arise in bone
marrow and migrate directly to peripheral lymphoid organs where they aggregate in
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germinal centers and can be stimulated to synthesize and secrete antibody are called
B cells. These B cells are distinguished by the presence of immunoglobulin on their
membrane surfaces when stained with fluorescenated anti-immunoglobulin. Lym-
phocytes which arise in the bone marrow but are modified by passage through the
thymus before they migrate to peripheral lymphoid organs are called T cells. T cell
functions include the cell-mediated immune response of delayed hypersensitivity and
allograft rejection. In addition, T cells can function as regulators of both B cell
antibody production and T cell cell-mediated immune responses. This regulation can
take the form of enhancing (helper T cells) or suppressing (suppressor T cells)
immune responses. These regulatory interactions can result from direct interaction of
regulatory T cells, or their products, with effector T or B cells; in addition, the
regulator T cells or their products can activate third-party T cells and macrophages
which then interact with the effector T or B cells. Thus, an aberration of macro-
phages, B cells, and/or T cells could result in altered immune responses.
The autoimmune diseases of New Zealand mice appear to reflect such aberrations.
Although clinically normal for the first three months of life, there are numerous
immunoregulatory abnormalities which can be detected. NZB B cells produce
excessive amounts of IgM at birth and continue to produce more IgM than other
mice throughout their lives [31]. This excessive IgM production is reflected in
excessive spontaneous production of antibodies to nucleic acids [32] and T cells[33].
Since IgM does not cross the placental barrier, the early occurrence of these
autoantibodies in New Zealand mice indicates synthesis by the young mouse rather
than passive transfer in utero. Furthermore, when compared to normal mice, NZB or
(NZB x NZW) F1 mice less than ten weeks ofage had excessive antibody responses to
the heterologous antigens of sheep erythrocytes [34], bovine serum albumin[35], and
bovine gamma globulin [36]. In addition to excessive B cell activity, the T cell
regulation of B cell function is shifted toward decreased suppression in New Zealand
mice [37]. The spontaneous evolution ofautoantibodies and hyperresponsiveness to
heterologous antigens could reflect an excessive helper T cell activity, defective
suppressor T cell activity, or both.
The induction of tolerance to foreign antigens results in a hyporesponsive state to
repeated antigen exposure. Compared to normal mice, autoimmune New Zealand
mice by five weeks of age are defective in their ability to develop tolerance to bovine
serum albumin [35], heterologous gamma globulin[36], polynucleotides [38-42], and
gross viral antigen [43]. In many cases, development of tolerance has been shown to
be dependent on T suppressor cells [44-47]. Thus, at a time when the (NZB x NZW)
F, mouse has lost self-tolerance as manifest by autoantibodies, it has also lost
experimental tolerance to heterologous antigen, suggesting an early loss of sup-
pressor function. Furthermore, neonatal thymectomy accelerates the development of
autoimmunity [48]. This concept was further supported by the demonstration that
thymuses from two-week-old (NZB x NZW) F1 mice, transplanted into neonatally
thymectomized (NZB x NZW) F1 mice, induced the recipients to regain the capacity
to develop tolerance to bovine gamma globulin, while anti-DNA titers were sup-
pressed [49].
Additional evidence for defective suppressor T cell function has evolved from
studies of such cells in normal mice. When spleen cells from normal mice are cultured
with the mitogen concanavalin A (Con A), a subpopulation of T cells are activated.
These Con A-activated T cells, and factors which these cells release into the culture
supernatants, can suppress antibody responses in vitro [50-52]. Con A-activated
spleen cells from four- and 18-week-old normal mice and (NZB x NZW) F1 mice were
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studied for their ability to suppress the pokeweed mitogen-driven splenic B cell
generation of IgM in vitro [53]. The Con A-activated spleen cells and culture
supernatants from young and old normal mice and young (NZB and NZW) F, mice
were equally suppressive. However the Con A-activated cells, and culture superna-
tants, from old (NZB x NZW) F, mice were unable to suppress such IgM production.
Conversely, the pokeweed mitogen-driven IgM responses ofthese old (NZB x NZW)
F, mice were suppressible by normal or young (NZB x NZW) F1 Con A-activated
cells or factors. Thus, as the (NZB x NZW) F, mice aged they lost their capacity to
generate suppressor activity, though their lymphocytes could still be suppressed by
exogenously supplied suppressor signals. When Con A was administered to young
(NZB x NZW) F1 mice they retained their capacity to develop tolerance to bovine
gamma globulin and their anti-DNA antibody titers decreased [54]. Furthermore, the
administration of supernatants of Con A-activated spleen cells to (NZB x NZW) F1
mice resulted in decreased immunoglobulin levels, anti-nuclear antibody, proteinu-
ria, and renal pathology [55]; the active factor(s) involved were ofvery low molecular
weight (! 1000 daltons) with one of the major mechanisms of suppression being in
vivo reduction in spleen cell number [56].
Recent investigations have suggested that the suppressor defect in New Zealand
mice is due to a defect in one of two cells which synergize in the induction of
suppression [57]. These investigations have been aided bythe identification ofunique
antigenic markers (Ly antigens) on the surfaces offunctionally different T cells [58].
Thymocytes are almost all Ly 1 2+3+ while peripheral helper T cells are Ly 1 2-3-
and suppressor T cells are Ly 1-2+3*. In normal mice a subpopulation ofimmature T
cells, Ly +2+3+, can be induced by Ly 1+ (helper) T cells to differentiate to Ly 2+3+
(suppressor) T cells [59]. Thus, a helper T cell not only enhances an effectorfunction,
but can also enhance feedback suppression ofthat same effectorfunction, resulting in
a controlled immune response. When NZB mice were compared to normal mice for
the presence of Ly 1+ 2+3+ spleen cells which could be induced to become suppressor
cells of a B cell antibody response to sheep erythrocytes, the NZB mice were
markedly deficient in those cells by one month of age [60]. Furthermore, we have
recently found that the naturally occurring anti-thymocyte antibody(natural thymo-
cytotoxic antibody or NTA) of NZB mice is specific for undifferentiated thymocytes
(presumably Ly 1'2+3 T cells) since Con A-activated thymocytes are relatively
resistant to lysis in NTA plus complement [61]. Perhaps the simultaneous occurrence
of detectable NTA, the deficiency of Ly 1+2'3' splenic precursor cells, and the onset
of a progressive aberration in suppressor function in NZB mice can be pathophysio-
logically correlated. The accelerated loss of suppressor cell function by neonatal
(NZB x NZW) F1 female mice administered NTA certainly supports such theory[62].
Further progression of aberrant immunoregulation in (NZB x NZW) F1 mice occurs
as the mice develop clinical disease by about six months of age. The hyper-
responsiveness to heterologous antigens seen at ten weeks of age changes to
hyporesponsiveness suggesting a loss of T helper cells [63].
Thus, the abnormalities of B cell function appear to result from loss of first
suppressor T cells and then helper T cells. Although such a functional loss could be
explained solely on the basis of a physical loss of lymphocyte subsets, the decreased
regulatory control may result from an inability of B cells, T cells, and/or macro-
phages to "communicate." A model for altered cell-to-cell "communication" has
evolved from studies ofthe autologous mixed lymphocyte reaction. In normal mice,
splenic cells can be stimulated to proliferate when cultured with autologous B cells
[64]. However, the auto-immune New Zealand mice fail to generate a proliferative
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response in an autologous mixed lymphocyte reaction. Furthermore, there is
evidence to suggest that B cells of autoimmune New Zealand mice are spontaneously
hyperactive [65].
In addition to the humoral defects discussed above, there are also abnormalities of
cell-mediated immunity which develop after the first 2-3 months of life [66-70]. By
six months of age they develop increased cytotoxic responses to alloantigen both in
vivo and in vitro [71]. Furthremore, spleen cells from six-month-old (NZB x NZW)
F, mice generated a greater graft-versus-host (GVH) reaction then spleen cells from
one-month-old mice in neonatal allogeneic hosts [72]; when young cells were mixed
with the old cells, the GVH reaction was decreased. By nine months of age, their
cytotoxic cell-mediated immunity changes from a hyper- to a hyporesponsive state
[71]. Furthermore, by 12 months of age the (NZB x NZW) F, spleen cells give a poor
GVH reaction in neonatal allogeneic recipients [72]; however by admixing a non-
stimulatory number of cells from six-month-old mice with the cells from 12-month-
old mice resulted in a GVH reaction suggesting the 12-month-old mice were deficient
in helper cells.
Recently a model for suppression ofT cell responses to alloantigen has suggested a
further defect in the regulation of cell-mediated immune responses in New Zealand
mice [73]. Mice, immunized with allogeneic spleen cells, have splenic T cells which,
on restimulation with the immunizing alloantigen, elaborate factor(s) which sup-
presses cytotoxic immune responses in vitro. The NZB mice, although having the
ability to elaborate such suppressive factor(s), are resistant to their suppressive
effects. This may represent a defect analogous to that seen with B cell suppression in
which there is a functional deficiency of cells through which feedback suppression
can be mediated.
Thus, the aberrations ofthe immune system in autoimmune New Zealand mice can
be viewed as an imbalance in normal regulatory mechanisms which culminates in
uncontrolled autoantibody production and resultant immune complex disease
resembling human SLE. The terminal malignancies which can develop may reflect
the combination of abnormal lymphocyte functions and the propensity toward
chromosomal abnormalities seen in these mice [74]. The role of genetic and viral
factors are probably of key etiologic importance and need to be more clearly defined.
The more recent elucidation of genetic control of both qualitative and quantitative
immune responses to antigenic stimulation further supports the importance of
genetic factors [75-79]. The genetic component could reflect the effects of a virus
integrated into and indistinguishable from the mouse genome. In addition, the
modifying effects of virus infection on the expression of autoimmunity [27,28]
suggest that viruses can stimulate or inhibit T and B cell functions, possibly by a
direct effect on the lymphocytes. In fact, propensity to produce antibodies to T cells
and DNA are inherited as independent traits [24]. Regardless of the underlying
etiologies of the various defects, the consequences are the appearance of
autoantibody-producing cell clones and a loss of regulatory and effector T cell
functions (Table 2). The ultimate pathological consequences are autoimmunity and
lymphoreticular malignancies.
Non-New Zealand Murine Models
Two new inbred mouse strains, MLR/1 and BXSB, have been developed as
models for autoimmunity and SLE [4]. These mice share many of the features of
autoimmune New Zealand mice [78]: B cell hyperactivity, autoantibodies, circulating




Active SLE NZB (NZB x NZW)F,
1. Spontaneous B-Cell Hyperactivity + + +
2. Impaired 1° Antibody Responses + + +
3. Impaired 1° Cell Mediated Immunity + + +
4. Relatively Normal 20 Immune Responses + + +
(Antibody and Cell Mediated)
5. Impaired Autologous MLR + + 9
6. Impaired Suppressor Function + + +
7. Impaired Helper Cell Function Variable + +
MRL/ I and BXSB mice and canine SLE have not been studied.
immune complex glomerulonephritis, and thymic cortical atrophy. In addition the
MRL/ I mice develop arthritis. While NZB and (NZB x NZW) F1 female mice have
accelerated disease activity compared to males, the incidence and severity ofdisease is
equal in male and female MRL/ 1 mice and is greatest in BXSB males. Furthermore
the MRL/ I and BXSB mice have a more accelerated onset of disease than New
Zealand mice, with a 50 percent mortality by six months of age.
Serum concentrations of immunoglobulin in BXSB and MRL/ I mice increase
with age and are five to nine times those of six-month-old normal mice. In addition,
MRL/ I mice have large quanitites of cryoglobulins. As the MRL/ 1 and BXSB mice
age, 23 percent and 43 percent, respectively, develop monoclonal gammopathies.
Abnormal autoantibody titers to nucleic acids and to double- and single-stranded
DNA increase with age; they are higher in MRL/I than BXSB mice, and are
associated chronologically with rising titers of circulating immune complexes and
falling serum complement levels and the onset of clinical disease. Anti-thymocyte
antibodies are elevated in BXSB mice but are of low titer in MRL/ I mice although
both have thymic atrophy.
The immune complex proliferative glomerulonephritis ofboth strains is character-
ized by the presence of high concentrations of antibodies to nucleic acids, double-
and single-stranded DNA in the renal eluates. Immunofluorescence staining of the
kidneys reveal striking deposits of immunoglobulin and complement involving both
the capillary loops and the mesangium. Lymphoid hyperplasia is most marked in
MRL/ I mice. Initial studies suggest that different proliferating subpopulations of
lymphocytes may be involved in each strain.
The similarities and differences of autoimmune MRL/ 1, BXSB and New Zealand
mice may allow genetic manipulations which will provide a better understanding of
the etiology of SLE. However, it should be realized that these new murine models
have not yet been extensively studied immunologically. Further data will need to be
gathered before their relativity to human disease is established. Nevertheless, these
mice provide an added spectrum of disease models ofhuman SLE. The MRL/ I mice
may represent the SLE-Sjogren's mix of human disease, while the BXSB mice may
provide further insight into the role of genetic or hormonal sex-linked influences on
the development of autoimmunity and neoplasia.
Canine Model
Canine SLE commonly presents as Coomb's positive hemolytic anemia, thrombo-
cytopenia, arthritis, and glomerulonephritis; less frequently the dogs have a facial
rash, alopecia, serositis, leukopenia, hepatosplenomegaly, and/or lymphodenopathy
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[3]. Antibodies to single-stranded DNA and double-stranded RNA and positive LE
preparations are common. Antibodies to double-stranded DNA are infrequent. All
breeds of dogs can be affected, with disease especially severe in young females.
Since canine SLE was first described by Lewis, Schwarts, and Henry in 1965,
studies have concentrated on genetic and viral contributions to the development of
disease. Three separate breeding lines were studied with 95 percent ofthe F, offspring
developing serologic abnormalities by 18 months of age; however, none of these F,
hybrids developed clinical SLE over seven years [79,80]. F, backcross and outcross
breedings failed to support a genetic basis for the serologic abnormalities.
These studies did, however, suggest the natural vertical passage of an infectious
agent. Experimental vertical transmission was subsequently demonstrated when cell-
free filtrates of SLE dog spleens were infused into normal puppies and mice [81].
Some of these recipients developed serologic abnormalities. Dogs receiving normal
spleen cell-free filtrates remained normal if housed separately. Natural horizontal
transmission was suggested when three of the recipients of normal spleen cell-free
filtrates developed abnormal serologic studies when housed with recipients of SLE
spleen cell-free filtrates.
Of the mice which received SLE dog spleen cell-free filtrates, 6 percent developed
lymphoid malignancies [81]. Cell-free filtrates of these tumors were then given to
normal dogs and syngeneic normal mice. Postive LE preparations were induced in
the dogs, and lymphoid tumors and antibodies to nucleic acids in the mice. One ofthe
murine tumors was a plasmacytoma (SP-104) which produced monoclonal IgA
against double-stranded DNA [82]. The relevance of these findings to humans was
supported by the finding that rabbit fluorescein-conjugated antibody to the purified
SP-104 virus stained lymphocytes from human SLE patients; in addition, anti-
lymphocyte antibodies from an SLE patient's sera could be absorbed with SP-104
[83].
Although these studies support the role of a transmissable agent in the pathogene-
sis of canine SLE, the clinical features still have not been transmissable, supporting
the concept of a multifactorial etiology of SLE. However, due to frequent canine-
human interaction, the theoretical consequences of an infectious (presumably viral)
agent which can be transmitted between species are ofepidemiologic importance [84].
Human SLE
The available evidence strongly suggests that human SLE is multifactorial in
etiology. Genetic factors have long been thought to be important. Recent studies of
families of patients with SLE have been reinforced by the finding that particular B
cell alloantigens occur with increased frequency in patients with SLE [85]. This is
analogous to the NZB mouse which spontaneously develops a lupus-like illness and
which has a limited number of genes predisposing to autoimmune features [19-25].
Genetic factors also are important in BXSB and MRL/ 1 mice and in SLE dogs.
Environmental factors such as viral infection (which may actually be endogenous
rather than exogenous) under certain circumstances seem to influence the appearance
of autoimmune manifestations [86]. Although the environmental factors may be
heterogenous, and their mechanisms of action diverse, the most likely deleterious
action is an adjuvant-like effect upon the immune system. In other words, any factor
which will stimulate the immune system, especially the B cell antibody-producing
part of the immune system, would exacerbate a tendency toward autoantibody
production.
Humans and mice with SLE appear to have generalized hyperactive B cell function
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[87,65]. Patients with active SLE have B cells and their progeny which produce
antibody to a variety of chemical haptens. Their increase in numbers of antibody-
forming cells is not limited to those producing autoantibodies, supporting the idea of
generalized B cell activation. Patients with active disease appear to be especially
abnormal with regard to IgG antibody-forming cells. Those with inactive disease may
have normal or increased numbers ofIgM antibody-forming cells, but not increased
IgG antibody-forming cells. This further points to a pathogenic role for IgG antibody
excess associated with active SLE as has been suggested for (NZB x NZW) F1 mice
[15,16].
A large number of T cell defects has been described in patients with SLE. Such
defects include reduced numbers of T cells [88,89], impaired delayed hypersensitivity
reactions [90,91], impaired response to T cell mitogens (including non-specific
mitogens, allogeneic cells, and antigens to which the cells had been sensitized)
[91-93], and impaired generation of suppressor cells [94]. Cells which contain large
quantities of T cell surface membrane antigens are preferentially lost [95,96]. These
studies point to a loss of a particular subpopulation of T cells. At least some of the
cells lost appear to be those capable of being activated to become suppressor cells.
The defect in suppression is an inability to produce suppressive signals rather than a
defect in responsiveness to suppressive signals. These findings are quite analogous to
those found in (NZB x NZW) F1 mice.
Active SLE patients, like NZB mice, also have marked defects in the autologous
mixed lymphocyte reaction [97]. With such a defect in T cell-B cell "communication,"
it is not surprising that so many abnormalities have been reported in active SLE and
in New Zealand mice.
Plasma and sera from many patients with active SLE, but not from normals or
patients with inactive SLE, were found to contain antibodies reactive with T cells by
indirect immunofluorescence, using the fluorescence-activated cell sorter and the
technique of flow microfluorometry [95]. These antibodies were largely of the IgM
class. They stained almost all T cell, whether from normals or patients with SLE. In
addition, patients with active SLE were found to have a decrease in T cells with high
density of T cell antigen (brightly staining cells) suggesting in vivo elimination by the
antibodies reactive with such T cells. The mechanism of in vivo elimination remains
unknown; it probably is alteration in circulatory pathways and removal of antibody
coated cells by the reticuloendothelial systems as occurs in New Zealand mice [67,98].
In vitro treatment of normal T cells with anti-T cell antibodies from most patients
with SLE led to killing of between 20 percent and 25 percent of T cells, but only if
complement was added [96]. Although the antibodies are capable of binding to allT
cells, there is a preferential killing of only a subpopulation of these T cells. Plasma
from patients with active SLE, in which anti-T cell antibodies were present, inhibited
the development of suppressor activity in the cultures of normal T cells activated by
Con A [96]. Absorption of the plasma containing anti-T cell antibodies with T cells,
but not non-T cells, could eliminate the suppressor-inhibiting activity of the SLE
plasma containing anti-T cell antibodies. The IgM, but not the IgG, fraction of the
plasma was shown to possess the inhibiting property and complement was found to
be necessary for the maximal effect of such anti-T cell antibodies. Anti-T cell
antibodies found to occur spontaneously in New Zealand mice have also been found
to preferentially kill suppressor cell precursors. This is true whether the antibodies
were studied in vitro or whether they were injected in vivo [61,62]. In patients with
SLE, there appears to be an analogous defect. The deficiency in generation of
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suppressor T cells of SLE patients can be reproduced in a normal human T cell
population by incubating them with IgM anti-T cell antibodies obtained from
patients with active SLE. These observations suggest the possibility that, as in NZB
mice, such antibodies may be the cause of some of the observed T cell defects in
patients with SLE. In addition, the class of SLE anti-T cell antibodies, IgM, is the
same as that found in NZB mice [33].
Studies to date suggest that different mechanisms may be operative in different
patients with SLE or in the same patient at different times. The various animal
models cover the spectrum of human SLE and support the possibility of a hetero-
geneous group of disorders with different genetic and immunologic bases as well as
different responses to a variety of environmental stimuli.
THERAPY
The treatment of human SLE has been guided for the most part by experimental
studies in autoimmune New Zealand mice. Therefore we will concentrate on those
studies. The therapeutic approaches to the autoimmune diseases of New Zealand
mice can emphasize either prophylaxis or treatment. Many of the prophylactic
studies are directed more toward understanding pathogenesis thantoward treatment.
Certainly the breeding studies of NZB mice suggest that the manifestations of
autoimmunity can be genetically modified. However, since our understanding of
human immunogenetics does not yet allow us to predict who will develop SLE, such
maneuvers are not yet applicable to the human illness.
Implication of a viral etiology has led to therapeutic trials in (NZB x NZW) F1
mice with the anti-viral agent Ribavirin [99]. The Ribavirin-treated mice lived longer
and had decreased proteinuria and antibodies to DNA; however, it is not clear that
the drug's beneficial effects are a result of the antiviral properties of the drug.
Attempts to modify the immune system have included treatment with immunosup-
pressive agents (Table 3). NZB mice have been treated with anti-lymphocyte serum
with suppression of the autoimmune hemolytic anemia, but with little favorable
effect on hyperglobulinemia, lymphoid infiltrates, or renal disease [100]. Similar
therapy of (NZB x NZW) F1 mice was found to accelerate disease [101,102], though
this may have been due to formation ofantibodies to the heterologous serum proteins
with resultant additional immune complexes which could be prevented by induction
TABLE 3
Modification of Early Disease
Murine Human
Active Disease NZB (NZB x NZW)F,
1. Genetic ? for J t or4
2. Viral ? or i tori
3. Immunologic Adjuvants
4. Immune Suppressors
5. Sex Hormones: Androgens ? ?
Estrogens t
6. Corticosteroids
7. Cytostatic, Cytotoxic Drugs ?
Worsening of disease
Suppression of disease
MRL and BXSB mice and canine SLE have not been comprehensively studied.
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TABLE 4
Treatment of Kidney Disease
(NZB NZW)F, Mice
Therapy Human Before Early Late
1. Corticosteroids ? + + 0
2. Immunosuppressive Drugs ? + + 0
3. Ribavirin ? + + 9
4. Prostaglandins 9 + + 9
5. CONSa + +
6. Anti-thymocyte Globulin ? + + 0
7. Tolerance to Nucleic Acids ? + 0 0
8. Androgens ? + +
9. Lymphoid Ablative Procedures ? + + 9
+ = Effective
0 = No change
- = Worsening
aCONS = Supernate of Concanavalin A activated cells
MRL I and BXSB mice and canine SLE have not been comprehensively studied.
of tolerance to these serum proteins prior to administering the anti-thymocyte serum
[103].
Recent studies suggest that treatment with exogenously produced suppressor
factors [55,56], prostaglandins [104], or cyclophosphamide and induction of toler-
ance to nucleic acids [105] may all lead to prolonged survival in (NZB x NZW) F1
mice. None of these modalities are currently applicable to the treatment of human
diseases, though they may be important therapeutic regimens in the future (Table 4).
Corticosteroids have been effective treatment for autoimmune hemolytic anemia of
NZB mice [106], and the symptoms of canine SLE. Corticosteroids, azathioprine,
and cyclophosphamide, given singly or in combination of two or three drugs, have all
been efficacious treatments for glomerulonephritis in (NZB x NZW) F1 mice if given
prior to the development of irreversible renal disease [107-109]; however, their
benefit if started after the development of advanced renal disease was marginal [110].
TABLE 5
Clinical Features of SLE
Murine Human
Active Untreated NZB (NZB x NZW) F1 MRL BXSB Canine
1. Immune Complex + Variable + + + +
Renal Disease
2. Hemolytic Anemia <I0% + <10% 0 + +
3. Rash + 0 0 0 0 +
4. Alopecia + 0 0 0 0 +
5. Arthritis + 0 0 + 0 +
6. Serositis Variable Variable Variable Variable Variable Variable
7. Splenomegaly Variable + + + + +
8. Lymphoid Infiltrates Variable + + + + +
into Organs
9. CNS Involvement Variable I? +
+ = Present in the majority




Active Untreated NZB (NZB x NZW)F, MRL I BXSB Canine
1. 1 E Cells + -20% + ? +
2. ANA + + + + + +
3. Anti-dsDNA + -20% + + + Rare
4. Anti-ssDNA + + + + + +
5. Anti-RNA + + + 9 +
6. Anti-erythrocyte -20% + Variable 10% 20% +
7. Anti-T Cell + + Earlier than in + 10% 40% ?
(NZB x NZW)F
8. Hyperglobulinemia + + + + + +
+ = Present in the majority
Therapeutic trials ofsimilar drug regimens in the treatment ofthe glomerulonephritis
of human SLE have yet to demonstrate clear-cut efficacy.
Another adjunct to treatment of canine and human SLE has been plasmapheresis
[111,112]; theoretically the removal of circulating autoantibodies and immune
complexes, coupled with immunosuppression, would reverse and/or prevent immune
complex function and its subsequent pathology.
Although the majority of symptoms and some signs of human, murine, or canine
SLE are responsive to corticosteroids, these drugs have a significant morbidity. In
addition there is still no treatment which dramatically alters the advanced life-
threatening features of SLE.
How Good are the Models?
Among the various animal models of human SLE one can find almost all of the
clinical, serological, pathological, epidemiologic, viral, genetic, and immune abnor-
malities found in patients with SLE (Tables 5, 6). Different models fit different types
of patients. NZB and BXSB mice are the best models of autoimmune hemolytic
anemia. (NZB x NZW) F, mice best represent lupus glomerulonephritis. MRL/ I
mice best represent Sjogren's Syndrome. In contrast to these inbred murine models,
dogs represent an outbred model of SLE. Of all these models, New Zealand mice
have been most completely studied. It is hoped that all these animals will provide a
clearer understanding of the etiology and pathogenesis of SLE and result in more
effective therapy.
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